

Luca Navarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1694776/publications.pdf>

Version: 2024-02-01

80
papers

1,537
citations

394421

19
h-index

361022

35
g-index

80
all docs

80
docs citations

80
times ranked

2498
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	2.2	6
2	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	1.9	16
3	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	2.6	9
4	Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease. <i>Rheumatology</i> , 2022, 62, 321-329.	1.9	15
5	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
6	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. <i>Scientific Reports</i> , 2022, 12, 7498.	3.3	7
7	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	5
8	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- β 2 and IL-6. <i>Pharmaceuticals</i> , 2022, 15, 622.	3.8	7
9	2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. <i>Biomedicines</i> , 2022, 10, 1675.	3.2	0
10	Beauty is not perfection: what Leonardo's Lady with an Ermine can suggest to aesthetic surgery. <i>European Journal of Plastic Surgery</i> , 2021, 44, 161-162.	0.6	2
11	JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107789.	2.4	2
12	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	5.8	38
13	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. <i>Autoimmunity Reviews</i> , 2021, 20, 102750.	5.8	36
14	Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. <i>Clinical Rheumatology</i> , 2021, 40, 4253-4258.	2.2	12
15	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 686457.	4.8	6
16	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	3.3	10
17	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	3.5	25
18	Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis. <i>Clinical and Experimental Medicine</i> , 2021, , 1.	3.6	2

#	ARTICLE	IF	CITATIONS
19	Erythema Multiforme Induced by Secukinumab. Journal of Clinical Rheumatology, 2021, 27, e177-e178.	0.9	4
20	Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre. Journal of Rheumatology, 2021, , jrheum.210441.	2.0	1
21	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. Clinical and Experimental Rheumatology, 2021, 39, 995-1002.	0.8	2
22	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
23	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. Rheumatology International, 2020, 40, 951-958.	3.0	34
24	New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scandinavian Journal of Rheumatology, 2020, 49, 75-76.	1.1	9
25	Enteropathic spondyloarthritis: Results from a large nationwide database analysis. Autoimmunity Reviews, 2020, 19, 102457.	5.8	18
26	Moderate-to-severe plaque psoriasis, described by PASI ≥10%, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10-year single-center retrospective study and clinical management of psoriatic patients with cardiovascular risk. Dermatologic Therapy, 2020, 33, e14451.	1.7	4
27	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. Rheumatology and Therapy, 2020, 7, 867-882.	2.3	21
28	One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opinion on Biological Therapy, 2020, 20, 813-821.	3.1	40
29	Homocysteinylated alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. Journal of Autoimmunity, 2020, 113, 102470.	6.5	17
30	Retention rates and identification of factors associated with anti-TNF±, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clinical Rheumatology, 2020, 39, 2663-2670.	2.2	17
31	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Review of Clinical Immunology, 2020, 16, 409-420.	3.0	21
32	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. Autoimmunity Reviews, 2020, 19, 102524.	5.8	231
33	Metabolic syndrome is associated with better quality of sleep in the oldest old: results from the "Mugello Study". Diabetology and Metabolic Syndrome, 2020, 12, 46.	2.7	1
34	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 785-796.	1.8	8
35	A longitudinal study on caring behaviors of Italian nursing students. Nurse Education Today, 2020, 88, 104377.	3.3	8
36	A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis. Rheumatology, 2020, 59, 1767-1769.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Phase angle could be a marker of microvascular damage in systemic sclerosis. <i>Nutrition</i> , 2020, 73, 110730.	2.4	11
38	Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. <i>Anticancer Research</i> , 2020, 40, 983-990.	1.1	17
39	Secukinumab-induced subacute cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2020, 33, e13417.	1.7	10
40	Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. <i>Journal of Experimental Pharmacology</i> , 2020, 12, 487-502.	3.2	1
41	Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 88-93.	0.8	5
42	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. <i>Drugs and Aging</i> , 2019, 36, 909-925.	2.7	15
43	The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 1705-1711.	1.6	20
44	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	3.5	40
45	Pattern of sleep dysfunction in systemic lupus erythematosus: a cluster analysis. <i>Clinical Rheumatology</i> , 2019, 38, 1561-1570.	2.2	7
46	Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 971-976.	2.2	10
47	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "without skin disease". <i>Clinical Rheumatology</i> , 2019, 38, 2547-2552.	2.2	21
48	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-7.	1.1	5
49	The Association of Olfactory Dysfunction, Frailty, and Mortality Is Mediated by Inflammation: Results from the InCHIANTI Study. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	2.2	42
50	Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Journal of Autoimmunity</i> , 2019, 107, 102387.	2.7	15
51	Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 71-76.	1.7	7
52	Pathogenesis of Psoriatic Arthritis. <i>Critical Reviews in Immunology</i> , 2019, 39, 361-377.	0.5	15
53	Clinical features of patients with systemic lupus erythematosus according to health-related quality of life, entity of pain, fatigue and depression: a cluster analysis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 535-539.	0.8	7
54	Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 99, 161-168.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Serum level of endostatin and digital ulcers in systemic sclerosis patients. International Wound Journal, 2018, 15, 424-428.	2.9	4
56	Erectile dysfunction: Imbalance between pro-angiogenic and anti-angiogenic factors in systemic sclerosis. European Journal of Internal Medicine, 2018, 53, e17-e18.	2.2	3
57	Leptin in autoimmune mechanisms of systemic rheumatic diseases. Cancer Letters, 2018, 423, 139-146.	7.2	16
58	In systemic sclerosis, microvascular and hands digital arteries damage correlates with serum levels of endostatin. Microcirculation, 2018, 25, e12449.	1.8	5
59	Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results. Journal of Immunology Research, 2018, 2018, 1-6.	2.2	27
60	Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE, 2018, 13, e0205506.	2.5	28
61	Physical activity and sedentary behavior in patients with Systemic Lupus Erythematosus. PLoS ONE, 2018, 13, e0193728.	2.5	48
62	Parasympathetic activity increases with digital microvascular damage and vascular endothelial growth factor in systemic sclerosis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 24-27.	0.8	3
63	Inflammation as a mediator of the association between osteoporosis and hearing loss in older subjects: a population-based study. European Review for Medical and Pharmacological Sciences, 2018, 22, 1451-1456.	0.7	3
64	Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy. Microvascular Research, 2017, 114, 41-45.	2.5	17
65	Intrarenal arterial stiffness is increased in systemic sclerosis patients with anti-ribonucleic acid polymerase III antibodies. Rheumatology, 2017, 56, 1039-1041.	1.9	2
66	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis), Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	8.8	107
67	Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus, 2017, 26, 1463-1472.	1.6	35
68	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clinical Rheumatology, 2017, 36, 251-260.	2.2	22
69	The relation between, metabolic syndrome and quality of life in patients with Systemic Lupus Erythematosus. PLoS ONE, 2017, 12, e0187645.	2.5	16
70	Polyunsaturated fatty acids: any role in rheumatoid arthritis?. Lipids in Health and Disease, 2017, 16, 197.	3.0	56
71	Relationship between leptin and regulatory T cells in systemic lupus erythematosus: preliminary results. European Review for Medical and Pharmacological Sciences, 2016, 20, 636-41.	0.7	24
72	The IL33/ST2 axis in Sjogren syndrome in relation to disease activity. European Review for Medical and Pharmacological Sciences, 2016, 20, 1295-9.	0.7	17

#	ARTICLE	IF	CITATIONS
73	Utility of ultrasound in the diagnosis of chronic worsened gout. Journal of Medical Ultrasonics (2001), 2013, 40, 467-469.	1.3	2
74	Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment. Current Medicinal Chemistry, 2013, 20, 3370-3396.	2.4	71
75	Systemic Lupus Erythematosus Patients with and without Neuropsychiatric Manifestations: A Neck and Transcranial Duplex Sonography Study. International Journal of Immunopathology and Pharmacology, 2012, 25, 1157-1165.	2.1	4
76	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews, 2011, 10, 631-635.	5.8	50
77	Leptin in immuno-rheumatological diseases. Cellular and Molecular Immunology, 2011, 8, 203-212.	10.5	45
78	Matters of the Heart: The Case of TNF-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3
79	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard. Clinical and Experimental Rheumatology, 0, , .	0.8	0
80	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 0, , .	0.8	0